<DOC>
	<DOCNO>NCT02896842</DOCNO>
	<brief_summary>Imatinib mesylate ( Gleevec/Glivec , IM ) currently gold standard CML-CP front line therapy . The recommend dose IM 400 mg/day . The rate complete cytogenetic response 3 , 6 12 month 27 % , 50 % 69 % respectively . The optimal IM daily dose yet determine randomize study address question on-going . First result TOPS trial ( EHA 2008 congress ) suggest rapid kinetic response patient treat imatinib high dose . Recent study reveal initial Imatinib plasmatic dosage predictive achieve complete cytogenetic response ( CCR ) dosage 1000 ng/ml associate high proportion major molecular response ( MMR ) ( Picard et al. , Blood 2007 , Larson et al . Blood 2007 ) . Results study Larson et al . indicate around 40 % patient trough plasmatic level 1000 ng/ml day 28 imatinib 400 mg/d . The major molecular response rate 12 month patient lower plasmatic level 25.4 % compare 40.1 % patient plasmatic dosage 800 1000 ng/ml . Investigators propose adapt imatinib daily dose case imatinib plasmatic level day 28 1000 ng/ml . Patients trough plasmatic dosage ≤ 1000 ng/ml randomize prospective adaptation strategy imatinib daily dose ( cohort 1 ) versus observation ( cohort 2 ) . The patient adequate imatinib dosage ( &gt; 1000 ng/ml ) follow accord ELN recommendation ( cohort 3 ) . Imatinib trough plasmatic level rechecked every month thereafter patient cohort 1 cohort 2 every three month cohort 3 . The first endpoint study rate major molecular response 12 month cohort 1 . Our hypothesis improve 12 month MMR rate optimize strategy ( cohort 1 ) 25 % MMR 12 month 40 % MMR 12 month .</brief_summary>
	<brief_title>A Prospective Randomized Phase II Study Evaluating Monitoring Imatinib Mesylate Plasmatic Through Level Patients Newly Diagnosed With CP-CML</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid , Chronic-Phase</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myelogenous , Chronic , BCR-ABL Positive</mesh_term>
	<mesh_term>Imatinib Mesylate</mesh_term>
	<criteria>1 . Male female patient ≥ 18 year 2 . Philadelphia chromosome positive newly diagnose chronic myelogenous leukaemia ( ≤ 4 month ) first chronic phase . 3 . Not previously treat tyrosine kinase inhibitor imatinib 4 . Prior treatment imatinib le 13 week 5 . Signed write inform consent 6 . Women childbearing potential ( WOCBP ) must use adequate method contraception 1 . Patients BCRABL positive , Philadelphia negative CML 2 . Patient previously treat TKI imatinib 3 . Pregnancy 4 . Active malignancy 5 . Concurrent severe disease exclude administration therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>